Interv Akut Kardiol 2012; 11(5-6): 183-186

Integrity - a new sinusoid coronary stent technology

Roman Štípal, Jiří Ostřanský, David Richter, Marcela Škvařilová, David Vindiš
I. interní klinika &ndash, kardiologická, LF UP a FN Olomouc

Continuous sinusoid technology is the result of more than 10 years of research and development. This technology is applied by Integrity

stent which demonstrates better flexibility, deliverability, conformity, radial strength and trackability in comparison with previous Driver

Sprint system and some other competitors. Integrity system is used by standard as well as by drug eluting stents.

Keywords: cobalt-chromium alloy, sinusoid technology, bare metal stent, drug eluting stent

Published: December 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Štípal R, Ostřanský J, Richter D, Škvařilová M, Vindiš D. Integrity - a new sinusoid coronary stent technology. Interv Akut Kardiol. 2012;11(5-6):183-186.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Butany J, Carmichael JK, Leong SW, Collins MJ. Coronary artery stents: identification and evaluation. J Clin Pathol 2005; 58: 795-804. Go to original source... Go to PubMed...
    2. Medtronic Coronary Stent Program. Continuous Sinusoid Technology. October 2010 ?m.
    3. Briguori C, Sarais C, Pagnotta P, Liistro F. In-stent restenosis in small coronary arteries. Impact of strut thickness. J Am Coll Cardiol 2002; 40: 403-409. Go to original source... Go to PubMed...
    4. Kastrati A, Mehilli J, Dirschinger J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 2001; 103: 2816-2821. Go to original source... Go to PubMed...
    5. Pache J, Kastrati A, Mehilli J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 2003; 41: 1283-1288. Go to original source... Go to PubMed...
    6. Hinuber C, Kleemann C, Friderichs RJ, et al. Biocompatibility and mechanical properties of diamond-like coatings on cobalt-chromium-molybdenum steel and titanium-aluminum-vanadium biomedical alloys. J Biomed Mater Res 2010; 95: 388-400. Go to original source... Go to PubMed...
    7. Gyongyosi M, Yang P, Khorsand A, et al. Longitudinal straightening effect of stents is an predictor for major adverse cardiac effect. J Am Coll Cardiol 2000; 35: 1580-1589. Go to original source... Go to PubMed...
    8. Moussa I, Di Mario C, Reimers B, et al. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome. J Am Coll Cardiol 1997; 29: 6-12. Go to original source... Go to PubMed...
    9. Mortier P, Van Loo D, De Beule M, et al. Novel technique for the quantitative analysis of wall coverage of deployed stents: comparison of five stents. EuroIntervention 2010; 6: Suppl H60.
    10. Legrand V, Kelbaek H, Hauptmann KE, et al. CLASS Study: Clinical and angiographic analysis with a cobalt alloy coronary stent (Driver) in stable and unstable angina pectoris. Amer J Cardiol 2006; 97: 349-352. Go to original source... Go to PubMed...
    11. Sketch MH Jr, Ball M, Rutherford B. DRIVER Registry: Evaluation of the Medtronic (Driver) cobalt-chromium alloy coronary stent system. Amer J Cardiol 2005; 95: 8-12. Go to original source... Go to PubMed...
    12. Fajadet J, Wijns W, Laarman GJ, et al. Randomized, doubleblind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatmen of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006; 114: 798-806. Go to original source... Go to PubMed...
    13. Rassmussen K, Maeng M, Kaltoft A, et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomized controlled superiority trial. Lancet 2010; 375: 1090-1099. Go to original source... Go to PubMed...
    14. Udipi K., Melder RJ, Chen M, et al. The next generation Endeavor Resolute Stent: role of the BioLinx(TM) Polymer System. EuroInterv 2007; 3: 137-139.
    15. Carter A, Melder RJ, Udipi K, et al. In vivo performance of a novel co-polymer system for extended release of zotarolimus in a next generation drug eluting stent. TCT Symposium, Washington DC, Oct 22-27, 2006.
    16. Serruys PW, Silber S, Garg S. Comparison of ZotarolimusEluting and Everolimus-Eluting Coronary Stents. N Engl J Med 2010; 363: 136-146. Go to original source... Go to PubMed...
    17. von Birgelen C, Basalus MWZ, Tandjung K, et al. A Randomized Controlled Trial in Second-Generation Zotarolimus-Eluting Resolute Stents Versus Everolimus-Eluting Xience V Stents in Real-Patients. The TWENTE Trial. J Am Coll Cardiol 2012; 59: 1350-1361. Go to original source... Go to PubMed...
    18. von Birgelen C, Verheij H. DUrable Polymer-based sTent CHallenge of Promus ElemEnt versus ReSolute Integrity (DUTCH PEERS): Randomized Multicenter Trial in All-Comers Population Treated Within Eastern NeThErlands-2 (TWENTE-2). Stichting Heart Centrum Twente, NTR2413.

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.